Skip to content
Home » Valentine's Day » Pfizer continues to have wild success and growth in revenue, but will a variant emerge that can beat vaccines?

Pfizer continues to have wild success and growth in revenue, but will a variant emerge that can beat vaccines?

Pfizer has proven itself throughout the pandemic as one of the leading vaccines to protect people from COVID-19. It also became the first vaccine to be fully FDA approved.

More people have used Pfizer compared to any other vaccine and the brand is slated to do $33.5 billion this year.

Pfizer wonders if their success will last as the virus seems to evolve and becomes better able to get around vaccines.


As variants appear, Pfizer’s scientists study them to determine its ability to get around the vaccine.

They will continue to study this until a strain that experts are almost certain will emerge that cannot be prevented with vaccines.

Pfizer CEO Albert Bourla has confidence in the company’s ability to adapt to all new variants.

The scientists have created vaccines for new variants as quickly as 95 days after its emergence.

As the need for new vaccines grows, so will the success of Pfizer’s company.



Categories: BusinessHealthNews

Top